T1	Participants 101 157	women with ErbB2 overexpressing metastatic breast cancer
T2	Participants 569 598	women with HER2-positive MBC.
T3	Participants 599 675	In this open-label, multicenter, phase II study, eligible patients (N = 112)
T4	Participants 1850 1887	patients with HER2-overexpressing MBC
